

A new integrated filling
system—brought
to you by the inventor
of Sevoflurane

We invented it.^{1,2}
We innovated it.³⁻⁶
*And now, we're bringing it to
you in an integrated system.*

Approved in over 75 countries, Baxter Sevoflurane is liquid anesthetic for inhalation, packaged in a convenient and non-reactive 250mL container made of aluminum—the most recyclable material available.⁷⁻¹⁴ As the market leader in inhaled anesthetics, Baxter listens to customer needs and provides the products you want. We're committed to the market—and to you. That's why we've responded by delivering an integrated valve system for our sevoflurane product.

We invented sevoflurane.

Sevoflurane was originally invented at Baxter in the late 1960s by B. Regan and his co-workers, and was patented in 1972.^{1,2}

We lead the way in technology.

Baxter developed and patented the 1-step and 3-step manufacturing processes for sevoflurane, and introduced the first integrated valve system for Suprane (desflurane).^{6,15,16} We remain the only manufacturer and supplier of all three modern inhaled agents.^{8,16,17}

We continue to innovate.

Baxter's aluminum container is light, includes a shrink-wrapped, tamper-evident seal, and the latest branded Safe-T-Seal valve comes permanently attached.^{8-10,18} It offers peace of mind and convenience—inside the operating room and in the pharmacy.

PrSEVOFLURANE (sevoflurane, USP) is indicated for inductions and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.⁸ PrSUPRANE (desflurane, USP) is indicated as an inhalation agent for the maintenance of general anesthesia following induction with agents other than SUPRANE in adults and in pediatric patients and subsequent endotracheal intubation in pediatric patients. SUPRANE is not recommended for mask induction of anesthesia in adults and in pediatric patients because of a high incidence of moderate to severe upper-airway adverse events.¹⁶



Sevoflurane from the provider you trust.



An integrated filling system to serve you better.

Convenience that saves time

Baxter's trademarked Safe-T-Seal valve is permanently attached, removing the need for an adaptor and any associated manipulations.^{8,19} When you don't have to worry about extra steps or accidentally disposing of adaptors, you may be able to improve your process in the OR.

No wasted product

With an integrated filling system, you don't have to be concerned with spilled product. The bottle is ready as-is and you can use the same bottle throughout its shelf life—until it's empty.^{8,20}

Aluminum matters.

Baxter Sevoflurane comes in a sleek, recyclable aluminum container—a unique design in the industry.^{8,21} It's not only user-friendly, it can even prevent degradation of the product.^{11–13}



Strong

Baxter's Sevoflurane aluminum container may reduce the safety hazards that come with cracked or broken bottles—including the risk of anesthetic leaks or exposure.^{24–25}



Suited for the product

Baxter's Sevoflurane epoxyphenolic-lined aluminum container does not react with the product—and unlike glass, cannot participate in a cascading degradation reaction initiated by Lewis acids.^{10–13}



Lightweight

Baxter's Sevoflurane aluminum container is designed to be easy to handle and easy to use. The smaller, lighter bottle¹⁸ facilitates smooth handling for the filling of vaporizers.



Earth friendly

Baxter's Sevoflurane aluminum container is recyclable and more than 7oz lighter than glass bottles¹⁸—which may result in easier transport and lower waste management costs.



Integrated system features the convenience of the permanently attached Safe-T-Seal valve.



CA2L9117SV
250 mL

DIN 02265974

Pr SEVOFLURANE
sevoflurane / sévoflurane, USP

99.97% v/v sevoflurane
(on anhydrous basis) /
sévoflurane à 99,97 % v/v
(dans une base anhydre)
Liquid for inhalation /
Liquide pour inhalation
Questions or concerns /
Des questions ou problèmes

Baxter
Baxter Corporation
Mississauga, ON L5N 0C2
1-888-719-9955

Inhalation Anesthetic
Dosage: Must be individualized and titrated to desired clinical effect according to patient's Product Monograph for information insert. See label for details.
Anesthésique par inhalation
Posologie: Doit être individualisée et titrée progressivement jusqu'à l'effet clinique désiré, en fonction de l'âge du patient. Consulter le monogramme du produit pour plus de renseignements. Ce médicament doit être utilisé avec précaution. Stocker entre 15°C et 30°C. Non inflammable/non explosif.

The Baxter vaporizer advantage.

Baxter vaporizer placement program

Baxter believes in investing in our customers, which is why we're committed to providing high-quality vaporizers to hospitals who choose Baxter Sevoflurane.

Rigorous Baxter qualification program

Baxter's rigorous chemical compatibility and functional testing and supplier quality audit programs assure the quality and performance of all sevoflurane vaporizers provided to our customers. We assure reliable equipment to support the delivery of our product to your patients.

Latest technology, trusted manufacturers

Baxter partners with the top vaporizer manufacturers. Our decision to work with trusted suppliers ensures we're able to equip all operating rooms with the latest technology of vaporizers and straightforward use.

Ongoing customer support

Our team is not only available for ongoing support, but we also provide vaporizer resources to help your processes remain smooth and simple. If there is ever a failure, we keep local swap pools and can supply replacement technology.



Baxter Sevoflurane with the integrated Safe-T-Seal valve and the GE Tec850 vaporizer.



Baxter Sevoflurane with the integrated Safe-T-Seal valve and the Dräger Vapor 2000 vaporizer.

SEVOFLURANE (sevoflurane, USP)

Indications and Clinical Use:

Sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

The minimum alveolar concentration (MAC) of Sevoflurane (sevoflurane) decreases with increasing patient age. The dose should be adjusted accordingly. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.

Contraindications:

- When general anesthesia is contraindicated
- Known hypersensitivity to Sevoflurane (sevoflurane), other halogenated anesthetics, or component of the container
- Patients in whom liver dysfunction, jaundice or unexplained fever, leukocytosis, or eosinophilia has occurred after a previous halogenated anesthetic administration
- Known or suspected susceptibility to malignant hyperthermia or in patients with a history of malignant hyperthermia

Relevant Warnings and Precautions:

- Administration only by qualified individuals trained in general anesthesia using a vaporizer specific to Sevoflurane in adequately equipped facilities
- Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.
- Can react with desiccated carbon dioxide absorbents to product carbon monoxide resulting in elevated carboxyhemoglobin levels
- May trigger malignant hyperthermia in susceptible individuals

- May lead to perioperative hyperkalemia in patients with neuromuscular disorders
- Caution should be exercised in administering general anesthesia, including sevoflurane, to patients with mitochondrial disorders.
- Sevoflurane may cause sensitivity hepatitis in patients who have been sensitized by previous exposure to halogenated anesthetics.
- Sevoflurane inhibits spontaneous respiration, which is enhanced with concurrent use of other inhalational and intravenous anesthetics. Respiration must be closely monitored and supported by assisted or controlled ventilation when necessary. Excessive respiratory depression may be related to depth of anesthesia and responds to decreasing the inspired concentration of sevoflurane.
- In pediatric patients, use of sevoflurane has been associated with seizures. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.
- MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old. In adults, the incidence of bradycardia is greater with sevoflurane than with isoflurane.
- May prolong QT interval in adults and children.

For more information:

Please consult the product monograph at http://www.baxter.ca/en_CA/assets/downloads/monographs/Sevoflurane_EN.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The product monograph is also available by calling us at 1-888-719-9955.

References:

1. Regan BM and Longstreet JC. U.S. Patent 3,683,092. 1972.
2. Regan BM and Longstreet JC. U.S. Patent 3,689,571. 1972.
3. Coon CL and Simon RL. U.S. Patent 4,250,334. 1981.
4. Coon CL and Simon RL. U.S. Patent 4,469,898. 1984.
5. Coon CL and Simon RL. EP 0 042 412. 1984.
6. Kudzma LV, et al. EP 1 277 724 B1. 1998.
7. Data on file. Worldwide marketing authorization. Baxter International, Inc. 2017.
8. Sevoflurane (sevoflurane, USP) Inhalation Anesthetic Product Monograph. Baxter Corporation. Mississauga, ON, January 2018.
9. Data on file. Yellow Sevoflurane integrated valve bottle. Baxter International, Inc. 2017.
10. Data on file. Sevoflurane bottle specifications. Baxter International, Inc. 2017.
11. Baker MT. Sevoflurane: are there differences in products? *Anesth Analg*. 2007; 104(6): 1447-51.
12. Data on file. Sevoflurane in aluminum bottle and degradation by Lewis Acids. Baxter International, Inc. 2012.
13. Abbott Labs. v. Baxter Pharm. Prods., Inc., 2005 U.S. Dist. LEXIS 44032 (N.D. Ill. 2005).
14. Aluminum Association. Aluminum recycling. <http://www.aluminum.org/sustainability/aluminum-recycling>. Accessed December 30, 2017.
15. Kudzma LV, Lessor RA, Rozov LA, Ramig K. U.S. Patent 5,886,239. 1999.
16. Suprane (desflurane, USP) Product Monograph. Baxter Corporation. Mississauga, ON, January 2018.
17. Forane (isoflurane, USP) Product Monograph. Baxter Corporation. Mississauga, ON, January 2018.
18. Data on file. Weights and dimensions. Baxter International, Inc. 2017.
19. Data on file. SAFE-T-SEAL trademark. Baxter International, Inc. 20.
20. Data on file. Sevoflurane in-use stability. Baxter International, Inc. 2017.
21. Rudzinski RV and Lessor RA. U.S. Patent 8,001,961 B2. 2011.
22. Baxter 2016 Corporate Responsibility Report. Baxter International, Inc. 23.
23. Data on file. Global market data. Baxter International, Inc. 2017.
24. Data on file. Baxter Healthcare Corp. Compression Testing of Bottles for Sevoflurane for the Baxter Healthcare Corporation. DDL Inc. Report number 0511010.
25. Data on file. Baxter Healthcare Corp. Sevoflurane-AbbVie (Quik Fil Drop Test). Report Number 1271570.

Our high standards come from experience.

Only Baxter supplies all three modern inhaled agents (sevoflurane, isoflurane, and desflurane).^{8,16,17} Our Sevoflurane is rated chemically and therapeutically equivalent to the AbbVie (formerly Abbott) brand.¹¹ It meets USP, EP, and all other established pharmacopeial standards for strength, quality, and purity—and it's approved in over 75 countries.⁷

Trusted leadership

- More than 35 years of industry related experience⁷
- Global leader in inhaled anesthesia since 2015⁷
- Leadership position in many markets
- Only manufacturer and supplier of the three modern inhaled anesthetics^{8,16,17}

Ongoing investment

- Innovator in container design and manufacturing
- Commitment to sustainability²²

- Products registered in >75 countries globally⁷
- Baxter inhaled anesthetics have treated over 750 million patients²³
- Broad geographic presence

Valuable offerings

- Robust and sustainable supply chain
- Automated distribution controls
- Anesthesia training and education
- Research contributions



¹⁷SEVOFLURANE (sevoflurane, USP) is indicated for inductions and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ⁸ ¹⁶SUPRANE (desflurane, USP) is indicated as an inhalation agent for the maintenance of general anesthesia following induction with agents other than SUPRANE in adults and in pediatric patients and subsequent endotracheal intubation in pediatric patients. SUPRANE is not recommended for mask induction of anesthesia in adults and in pediatric patients because of a high incidence of moderate to severe upper-airway adverse events. ¹⁶ ¹⁷FORANE (isoflurane, USP) is indicated for induction and maintenance of general anesthesia.¹⁷ Please consult the Suprane, Sevoflurane and Forane Product Monograph at <http://www.baxter.ca/en/products-expertise/all-products.page?> for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monographs are also available by calling us at 1-855-584-1368.

Baxter and Safe-T-Seal are trademarks of Baxter International Inc.
CAMP/SG149/18-0003 May 2018

Baxter